Dir
Elisabeth Björk, M.D., Ph.D. is an accomplished pharmaceutical executive and independent director at Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), where she recently purchased 10,000 shares on August 27, 2025, at $3.44 per share.[[4]](https://www.ainvest.com/news/rocket-pharmaceuticals-director-bjork-elisabeth-buys-10-000-shares-3-44-share-2601/)[[5]](https://www.tradingview.com/news/tradingview:8dcc22136c220:0-rocket-pharmaceuticals-director-elisabeth-bjork-buys-10-000-shares/) With over 30 years of experience in clinical practice, academic research, and drug development, she previously held senior leadership roles at AstraZeneca, including Senior Vice President and Head of the Obesity franchise, as well as Head of Late-stage Development for Cardiovascular, Renal, and Metabolism (CVRM) R&D, where she advanced blockbuster drugs and transformed the CVRM portfolio.[[1]](https://www.nodthera.com/news/nodthera-announces-appointment-of-elisabeth-bjork-as-board-member/)[[2]](https://www.camurus.com/about-us/board-of-directors/elisabeth-bjork/)[[3]](https://rocketpharma.com/about-us)
Dr. Björk serves on the boards of multiple public and private biotech companies, including Pharvaris N.V. (NASDAQ: PHVS), Vicore Pharma AB (STO: VICO), Camurus AB (STO: CAMX), and NodThera, leveraging her expertise in cardiometabolic diseases, regulatory submissions, and commercialization.[[1]](https://www.nodthera.com/news/nodthera-announces-appointment-of-elisabeth-bjork-as-board-member/)[[2]](https://www.camurus.com/about-us/board-of-directors/elisabeth-bjork/) An endocrinologist by training, she earned her M.D. from the Karolinska Institute and a Ph.D. in Endocrinology from Uppsala University, where she also served as Associate Professor of Medicine.[[1]](https://www.nodthera.com/news/nodthera-announces-appointment-of-elisabeth-bjork-as-board-member/)[[2]](https://www.camurus.com/about-us/board-of-directors/elisabeth-bjork/)
View full insider profile →
Discussion